Sponsors and Exhibitors
Sundia is a leading CRO company located in the Zhangjiang Hightech Park of Shanghai, China. Sundia was founded by a group of veterans of the US biopharmaceutical industry. The founding team has received advanced doctorate degrees or training in US and each has got over 10-years of extensive working and/or management experience in the pharmaceutical & biotech industry. Sundia has always focused on customers' needs since we believe customer’s success is our success. Sundia has provided "One Stop for All" CRO services for more than 120 companies in US, Europe and Japan to fit the increasing market demands for better and more efficient drug discovery & development process. Our integrated services include custom synthesis, medicinal chemistry, library production, hit generation, lead optimization, process chemistry R & D, API cGMP production, formulation development, PK in vitro & in vivo research & pre-clinical study. Sundia currently has over 190,000 sq. ft office/labs & 14 acres space of API/GMP manufacture facility and has employed around 700 scientists, of whom 20% are Ph.D.'s, 55% MS's, and 25% BS's.
For more information please visit our website, http://www.sundia.com
Pharma is entering a transformative business environment that creates an unprecedented focus on organizational decision making and its ties to Return-On-Investment (ROI) and business productivity. This focus has special relevance for R&D functions where decisions are based on the constant expansion of scientific and medical knowledge and can have long term positive business impact. At Elsevier, we enable biomedical R&D by delivering essential information for target finding and validation, molecule design, model validation and clinical trial design. The information we deliver spans peer reviewed published literature, conferences and patents and covers the latest biomedical research and clinical information essential for R&D productivity
Molecular Devices provides one of the widest ranges of bioanalytical systems for life science and drug discovery research available from a single supplier. Our systems are built on proprietary technology platforms that deliver high performance, flexibility, and reliability. Molecular Devices acquired Universal Imaging Corporation in 2002, Axon Instruments in 2004, and Blueshift Technologies in 2008, broadening its portfolio to include electrophysiology products, scanners and analysis software for microarrays, and workstations for cell-based screening using high-resolution imaging. The plate readers contain high efficiency tunable absorbance, fluorescence intensity, luminescence, TRF, FP, FRET, TR-FRET, HTRF detection modes and endpoint, kinetic, spectral & well scanning read types.